Sepset Biosciences Developing Sepsis Test Based on Cellular Reprogramming Signature

Sep 16, 2016

|

Premium

NEW YORK (GenomeWeb) – Sepset Biosciences, a company spun out by the Centre for Drug Research and Development (CDRD), a Canadian national drug development and commercialization center, is developing a rapid diagnostic blood test to aid in the early, targeted treatment of sepsis.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Apr

23

Featured Webinar

AMP/ACMG/CAP Cancer Sequence Variant Guidelines: A Two-Year Status Report

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence.

Apr

24

Featured Webinar

Metabolomics Analyses to Elucidate Systemic Processes in Human Health and Disease

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu